/Biogen%20Inc%20logo%20on%20laptop-by%20monticello%20via%20Shutterstock.jpg)
Cambridge, Massachusetts-based Biogen Inc. (BIIB) operates as a leading biotech firm, pioneering innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and communities. Valued at $26.6 billion by market cap, it has a deep understanding of human biology and leverages different modalities to advance first-in-class treatments or therapies that deliver superior outcomes.
Companies worth $10 billion or more are generally described as "large-cap stocks." Biogen fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the biotech industry.